Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scios/Wyeth-Ayerst Fiblast agreement calls for $12 mil. up-front to Scios.

Executive Summary

SCIOS/WYETH-AYERST FIBLAST AGREEMENT INCLUDES $12 MIL. UP FRONT cash payment from Wyeth-Ayerst, the companies announced Oct. 23. The joint development and commercialization agreement for Scios' trafermin (basic fibroblast growth factor) for the treatment of neurological and cardiovascular disorders will also include up to $32 mil. in milestone payments to Scios and a $12 mil. credit line from Wyeth-Ayerst to fund expansion of the Fiblast manufacturing facility.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel